Market Overview:
The global bio-therapeutic glycoproteins market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of chronic diseases, rising demand for biologic drugs, and technological advancements in the field of glycoprotein therapeutics. Based on type, the global bio-therapeutic glycoproteins market is segmented into antisera, cytokines, clotting factors, hormones, enzymes and enzyme inhibitors. The antisera segment is expected to account for the largest share of the global bio-therapeutic glycoproteins market in 2018. This segment is also projected to grow at a CAGR of 7.8% during the forecast period from 2018 to 2030. This growth can be attributed to increasing demand for monoclonal antibodies (mAbs) as therapeutic agents and rising incidence of cancer worldwide.
Product Definition:
Bio-Therapeutic Glycoproteins are proteins that have been modified to include a sugar molecule. This modification helps the protein to interact with other molecules in the body, which can improve its effectiveness. Bio-Therapeutic Glycoproteins can be used to treat a variety of diseases and conditions, including cancer, AIDS, and autoimmune disorders.
Antisera:
Antisera is a vaccine preparation used to stimulate the immune system to produce antibodies against an antigenic substance. The most common antigens are bacteria, viruses, toxins, and tumor cells.
Cytokines:
Cytokines are interleukins, interferons, and lymphokines. They are a group of proteins that regulate the immune system by communicating with receptors located on white blood cells (WCB), fibroblasts, endothelial cells, and other immune system components. There are many different types of cytokines produced by the body’s immune system in response to pathogens or damaged tissue.
Application Insights:
On the basis of application, the global bio-therapeutic glycoproteins market has been segmented into oncology and haematology, diabetes, cardiology, inflammatory diseases and others. Oncology dominated the overall market in terms of revenue share in 2017. This is due to a high prevalence of cancer worldwide coupled with increasing R&D investments by various players operating in this sector. For instance, F Hoffmann-La Roche Ltd., one of the leading biopharmaceutical companies has developed a new strategy for treating blood disorders such as anaemia and leukaemia by collaborating with researchers from China¢â‚¬â„¢s Tsinghua University to develop an enzyme replacement therapy for cancer treatment using gene therapy techniques.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period due to increasing R&D investments by pharmaceutical and biotechnology companies. Moreover, rising prevalence of chronic diseases such as cancer, diabetes, and others are anticipated to boost product demand in North America over the forecast period.
Asia Pacific is expected to witness lucrative growth over the next eight years owing to untapped opportunities in this region along with high unmet clinical needs of a large population pool that includes children & adolescents as well as pregnant women suffering from various disorders such as cancer, autoimmune diseases (rheumatoid arthritis), infectious diseases (HIV/AIDS), cardiovascular disease etc., which can be treated using glycoproteins therapeutically.
Growth Factors:
- Increasing prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders is expected to drive the demand for bio-therapeutic glycoproteins over the forecast period.
- Growing awareness about the benefits of using bio-therapeutic glycoproteins in the treatment of various diseases is anticipated to propel market growth.
- Rising number of research and development activities for novel therapeutics is projected to fuel market growth over the next few years.
- Technological advancements in glycoprotein production are likely to provide lucrative opportunities for market players in the near future.
Scope Of The Report
Report Attributes
Report Details
Report Title
Bio-Therapeutic Glycoproteins Market Research Report
By Type
Antisera, Cytokines, Clotting Factors, Hormones, Enzymes, Enzyme Inhibitors
By Application
Oncology and Haematology, Diabetes, Cardiology, Inflammatory Diseases, Others
By Companies
Genentech, Hoffmann-La Roche, Genzyme Corp, Abbott Laboratories, Amgen, Biogen, Merck, GlaxoSmithKline, Novartis Pharmaceuticals Corp, Genentech
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
204
Number of Tables & Figures
143
Customization Available
Yes, the report can be customized as per your need.
Global Bio-Therapeutic Glycoproteins Market Report Segments:
The global Bio-Therapeutic Glycoproteins market is segmented on the basis of:
Types
Antisera, Cytokines, Clotting Factors, Hormones, Enzymes, Enzyme Inhibitors
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Oncology and Haematology, Diabetes, Cardiology, Inflammatory Diseases, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Genentech
- Hoffmann-La Roche
- Genzyme Corp
- Abbott Laboratories
- Amgen
- Biogen
- Merck
- GlaxoSmithKline
- Novartis Pharmaceuticals Corp
- Genentech
Highlights of The Bio-Therapeutic Glycoproteins Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Antisera
- Cytokines
- Clotting Factors
- Hormones
- Enzymes
- Enzyme Inhibitors
- By Application:
- Oncology and Haematology
- Diabetes
- Cardiology
- Inflammatory Diseases
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Bio-Therapeutic Glycoproteins Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Bio-therapeutic glycoproteins are proteins that have been specifically designed to interact with specific receptors on cells in the body. These proteins can help to improve the function of cells by regulating their activity and communication.
Some of the major players in the bio-therapeutic glycoproteins market are Genentech, Hoffmann-La Roche, Genzyme Corp, Abbott Laboratories, Amgen, Biogen, Merck, GlaxoSmithKline, Novartis Pharmaceuticals Corp, Genentech.
The bio-therapeutic glycoproteins market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Bio-Therapeutic Glycoproteins Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Bio-Therapeutic Glycoproteins Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Bio-Therapeutic Glycoproteins Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Bio-Therapeutic Glycoproteins Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Bio-Therapeutic Glycoproteins Market Size & Forecast, 2018-2028 4.5.1 Bio-Therapeutic Glycoproteins Market Size and Y-o-Y Growth 4.5.2 Bio-Therapeutic Glycoproteins Market Absolute $ Opportunity
Chapter 5 Global Bio-Therapeutic Glycoproteins Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Bio-Therapeutic Glycoproteins Market Size Forecast by Type
5.2.1 Antisera
5.2.2 Cytokines
5.2.3 Clotting Factors
5.2.4 Hormones
5.2.5 Enzymes
5.2.6 Enzyme Inhibitors
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Bio-Therapeutic Glycoproteins Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Bio-Therapeutic Glycoproteins Market Size Forecast by Applications
6.2.1 Oncology and Haematology
6.2.2 Diabetes
6.2.3 Cardiology
6.2.4 Inflammatory Diseases
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Bio-Therapeutic Glycoproteins Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Bio-Therapeutic Glycoproteins Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Bio-Therapeutic Glycoproteins Analysis and Forecast
9.1 Introduction
9.2 North America Bio-Therapeutic Glycoproteins Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Bio-Therapeutic Glycoproteins Market Size Forecast by Type
9.6.1 Antisera
9.6.2 Cytokines
9.6.3 Clotting Factors
9.6.4 Hormones
9.6.5 Enzymes
9.6.6 Enzyme Inhibitors
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Bio-Therapeutic Glycoproteins Market Size Forecast by Applications
9.10.1 Oncology and Haematology
9.10.2 Diabetes
9.10.3 Cardiology
9.10.4 Inflammatory Diseases
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Bio-Therapeutic Glycoproteins Analysis and Forecast
10.1 Introduction
10.2 Europe Bio-Therapeutic Glycoproteins Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Bio-Therapeutic Glycoproteins Market Size Forecast by Type
10.6.1 Antisera
10.6.2 Cytokines
10.6.3 Clotting Factors
10.6.4 Hormones
10.6.5 Enzymes
10.6.6 Enzyme Inhibitors
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Bio-Therapeutic Glycoproteins Market Size Forecast by Applications
10.10.1 Oncology and Haematology
10.10.2 Diabetes
10.10.3 Cardiology
10.10.4 Inflammatory Diseases
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Bio-Therapeutic Glycoproteins Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Bio-Therapeutic Glycoproteins Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Bio-Therapeutic Glycoproteins Market Size Forecast by Type
11.6.1 Antisera
11.6.2 Cytokines
11.6.3 Clotting Factors
11.6.4 Hormones
11.6.5 Enzymes
11.6.6 Enzyme Inhibitors
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Bio-Therapeutic Glycoproteins Market Size Forecast by Applications
11.10.1 Oncology and Haematology
11.10.2 Diabetes
11.10.3 Cardiology
11.10.4 Inflammatory Diseases
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Bio-Therapeutic Glycoproteins Analysis and Forecast
12.1 Introduction
12.2 Latin America Bio-Therapeutic Glycoproteins Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Bio-Therapeutic Glycoproteins Market Size Forecast by Type
12.6.1 Antisera
12.6.2 Cytokines
12.6.3 Clotting Factors
12.6.4 Hormones
12.6.5 Enzymes
12.6.6 Enzyme Inhibitors
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Bio-Therapeutic Glycoproteins Market Size Forecast by Applications
12.10.1 Oncology and Haematology
12.10.2 Diabetes
12.10.3 Cardiology
12.10.4 Inflammatory Diseases
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Bio-Therapeutic Glycoproteins Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Bio-Therapeutic Glycoproteins Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Bio-Therapeutic Glycoproteins Market Size Forecast by Type
13.6.1 Antisera
13.6.2 Cytokines
13.6.3 Clotting Factors
13.6.4 Hormones
13.6.5 Enzymes
13.6.6 Enzyme Inhibitors
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Bio-Therapeutic Glycoproteins Market Size Forecast by Applications
13.10.1 Oncology and Haematology
13.10.2 Diabetes
13.10.3 Cardiology
13.10.4 Inflammatory Diseases
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Bio-Therapeutic Glycoproteins Market: Competitive Dashboard
14.2 Global Bio-Therapeutic Glycoproteins Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Genentech
14.3.2 Hoffmann-La Roche
14.3.3 Genzyme Corp
14.3.4 Abbott Laboratories
14.3.5 Amgen
14.3.6 Biogen
14.3.7 Merck
14.3.8 GlaxoSmithKline
14.3.9 Novartis Pharmaceuticals Corp
14.3.10 Genentech